SCHEMBL7103058

SCHEMBL7103058

Cn1c(=O)n(Cc2ccc(Cl)cc2)c(=O)c2cc(C(=O)O)ncc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.47
SLC22A8 Q8TCC7 1/20 0.47
UBE2N P61088 1/20 0.46
P2RX3 P56373 6/20 0.46
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
TRPC5 Q9UL62 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 2/20 0.42
HIF1A Q16665 1/20 0.42
GAA P10253 1/20 0.42
KDM4E B2RXH2 1/20 0.42
KDM4A O75164 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6255569 0.91 MMP13 (0.53) MMP13SLC22A8TRPC5HTTKDM4E
SCHEMBL7097739 0.90 MMP13 (0.46) MMP13SLC22A8HDAC1HDAC8HDAC6
SCHEMBL7018710 0.90 MMP13 (0.46) MMP13SLC22A8HDAC1HDAC8HDAC6
SCHEMBL7102299 0.90 GRIN1 (0.44) MMP13SLC22A8P2RX3
SCHEMBL7022157 0.89 MAPT (0.53) MMP13SLC22A8UBE2NLMNAMAPT
SCHEMBL7018972 0.88 GRIN1 (0.44) MMP13SLC22A8
SCHEMBL7100732 0.88 PIK3CD (0.51) MMP13SLC22A8LMNAMAPTKDM4E
SCHEMBL7097229 0.85 MEN1 (0.47) P2RX3TRPC5ALDH1A1TSHRL3MBTL1
SCHEMBL7014083 0.83 MAPK1 (0.55) MMP13SLC22A8LMNAMAPTHIF1A
SCHEMBL7097608 0.83 MAPT (0.47) MMP13SLC22A8LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MMP13 1/4885SLC22A8 315/4885UBE2N 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.